性福网站 I 男的操女的网站 I 香蕉网伊 I 亚洲国产精品一区 I 久草视频播放 I 亚洲字幕成人中文在线观看 I 国产精品亚洲一区二区三区在线观看 I 亚洲制服另类 I 国内精品久久久久伊人aⅴ I 宅男极品番号社 I 亚洲天堂网址 I 日本少妇xxxx I 青娱乐在线视频免费观看 I 亚洲精品综合在线观看 I 日韩电影网址 I 免播放器av I 国产精品一区无码 I 亚洲电影中文字幕 I 综合激情小说 I 一级欧美 I 黄在线网站 I 996久久国产精品线观看 I 97在线中文字幕 I 久久99精品国产麻豆蜜芽 I 岛国 中文字幕 I 日本成人h动漫在线 I 99久久婷婷国产综合精品电影√ I 电影在线一区二区 I 三级黄色,未满18 I 男女做爰猛烈啪啪吃奶图片 I 水野优香av在线区二区 I 日本高清在线www3344 I 天天做天天爱夜夜夜爽毛片 I 国产精品久久久. I 亚洲国产女人aaa毛片在线动漫 I 乱码1区2区3区4区 I 天堂av男人 I 国产精品26p I 亚洲欧美国产中文

一.產品名稱：

通用名稱：甲狀旁腺激素1-34 ELISA試劑盒

英文名稱：PTH 1-34 ELISA Kit

二.PTH 1-34 ELISA Kit介紹：

Teriparatide (rhPTH 1-34) is a recombinant human parathyroid hormone derivative consisting of the first 34 amino acids of the hormone. Teriparatide was approved as a drug by the FDA in 2002 and is sold by Eli Lilly & Co. under the brand name Forteo. Teriparatide is indicated for use in patients with osteoporosis. It is currently administered by injection and has an anabolic effect on bone, binding to the PTH/PTHrp Type 1 receptor with the same affinity as the intact molecule, PTH (1-84). This receptor activation results in a series of events leading to the formation of new trabecular and cortical bone. Research is continuing at pharmaceutical and biotech companies to pursue similar drugs and alternate delivery pathways.
Immunogenicity for this drug, defined as the presence of antibodies to human PTH (1-34), was detected in 2.8% of women receiving teriparatide during the clinical trials of Forteo. The detection of these
circulating antibodies may be of clinical relevance for the proper assessment of patients.

如需了解更多產品資料，請北京科瑞美公司。